Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels

Jacqueline de Graaf1*, Pernette R. W. de Sauvage Nolting2, Marjel van Dam2, Elizabeth M. Belsey3, John J. P. Kastelein2, P. Haydn Pritchard4 and Anton F. H. Stalenhoef1

1Department of General Internal Medicine, University Medical Centre Nijmegen, Nijmegen, The Netherlands
2Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands
3Department of Statistics, Division of Infectious Diseases, Northwestern University, Chicago, IL, USA
4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

(Received 1 October 2001 – Revised 29 May 2002 – Accepted 18 June 2002)

In a randomized, double-blind, placebo-controlled trial we evaluated the effect of dietary chocolates enriched with a wood-based phytosterol–phytostanol mixture, containing 18 % (w/w) sitostanol, compared with placebo dietary chocolates in seventy subjects with primary hypercholesterolaemia (total cholesterol levels below 8 mmol/l). For 4 weeks, participants consumed three servings of the phytosterol-enriched chocolate/d that provided 1·8 g unesterified phytosterols/d or a placebo chocolate in conjunction with a low-fat, low-cholesterol diet. Plasma total and LDL-cholesterol levels were statistically significantly reduced by 6·4 % (±0·44 mmol/l) and 10·3 % (±0·49 mmol/l), respectively, after 4 weeks of phytosterol-enriched-chocolate treatment. Plasma HDL-cholesterol and triacylglycerol levels were not affected. Consumption of phytosterol-enriched chocolates significantly increased plasma lathosterol concentration (+20·7 %), reflecting an increased endogenous cholesterol synthesis in response to phytosterol-induced decreased intestinal cholesterol absorption. Furthermore, the chocolates enriched with phytosterols significantly increased both plasma sitosterol (+95·8 %) and campesterol (+64·1 %) levels, compared with the placebo chocolate group. However, the absolute values of plasma sitosterol and campesterol remained within the normal range, that is, below 10 mg/l. The chocolates with phytosterols were palatable and induced no clinical or biochemical side effects. These findings indicate that dietary chocolate enriched with tall oil-derived phytosterols (1·8 g/d) is effective in lowering blood total and LDL-cholesterol levels in subjects with mild hypercholesterolaemia and thus may be helpful in reducing the risk of CHD in these individuals.

Recent studies have convincingly shown that serum total and LDL-cholesterol reduction significantly decreases total and coronary mortality in primary and especially secondary prevention of CHD (Scandinavian Simvastatin Survival Study Group, 1994; Shephard et al. 1995). Dietary modification can reduce cholesterol levels and the risk of CHD, but for a significant portion of the population, treatment with lipid-lowering agents is required for effective cholesterol reduction. There is an urgent clinical need for a low-cost, low-risk intervention that can treat those individuals that have not responded well to dietary modification, and where pharmaceutical intervention is not desirable. Consumption of foods containing phyto- (i.e. plant) sterols has the necessary characteristics to meet that need.

There has been renewed interest in the use of phytosterols for the treatment of hypercholesterolaemia, since they have potent cholesterol-lowering effects, as shown in normo- and hypercholesterolaemic men and women with or without CHD (Miettinen et al. 1995; Gylling et al. 1997; Westrate et al. 1998; Plat & Mensink, 2000), children (Gylling et al. 1995; Tammi et al. 2000) and diabetics (Gylling & Meittinen, 1994, 1996). Phytosterols interfere with cholesterol metabolism, especially intestinal cholesterol

Due to the lack of toxicity in man, phytosterols have an important advantage over existing pharmaceutical agents in the potential prevention of atherosclerotic vascular disease. Therapeutically, phytosterols could be positioned after diet modification or used in conjunction with other agents having cholesterol-lowering activity (Blair et al. 2000).

The objective of the present study was to develop a food-based product that lowers undesirable blood cholesterol levels, through the addition of safe, effective and undetectable phytosterols. In the context of a clinical outpatient-based study, it was important that this food be both palatable and easy to consume with each of three meals/d. To address this objective, dietary chocolate containing a phytosterol mixture was administered to study subjects for 4 weeks. Specifically, diets containing chocolate alone were compared with diets containing chocolate supplemented with tall oil-derived sterols. Tall oil-derived phytosterols consist of a proprietary mixture of four phytosterols (β-sitosterol, sitostanol, campesterol, stigmastanol) in the approximate ratio of 60:20:14:3. It was anticipated that the study results would assist in the development of a chocolate that would offer advantages in the control of plasma LDL levels.

The overall objective of the study was to examine whether the addition of a tall oil-derived phytosterol mixture to dietary chocolate results in a reduction in total and LDL-cholesterol levels compared with chocolate alone, in mildly hypercholesterolaemic individuals.

Subjects and methods

Subjects

A total of seventy volunteers, including both men and women, with primary hypercholesterolaemia were recruited by advertisement in local newspapers from inhabitants of Nijmegen, Rotterdam, Amsterdam and Groningen (The Netherlands). To be eligible for enrolment, participants had to meet the following inclusion criteria: age 21–75 years; fasting total cholesterol level between 5.5 and 8.0 mmol/l; fasting LDL-cholesterol level ≥ 3.5 mmol/l; triacylglycerol level < 4.0 mmol/l; HDL levels ≥ 0.8 mmol/l and BMI < 35 kg/m². Eligible subjects reported consuming ten or fewer units of alcohol (1 unit = 10 ml ethanol)/week. Premenopausal women had to have been surgically sterilized or highly unlikely to conceive, i.e. taking oral contraceptives or with an intra-uterine device in place for 3 months. Exclusion criteria were secondary causes for dyslipidaemia, including a history of diabetes mellitus, hypothyroidism and hepatic or renal impairment, or apolipoprotein phenotype E2/E2. Furthermore, eligible subjects reported not having a current disease or history of malignancy, uncontrolled hypertension, unstable angina or myocardial infarction within 3 months before the study, familial sitosterolaemia, ileal bypass surgery or any gastrointestinal disorder that could affect cholesterol or fat absorption. Except for the phytosterol mixture, no other cholesterol-lowering agents including β-hydroxy-β-methylglutaryl-CoA reductase inhibitors, fibrates, and bile-acid resins were to be taken during the study. In the placebo group, ten subjects used other medication including post-menopausal oestrogen therapy (n 1), anti-thrombolytic medication (n 3), β-blockers (n 3) and angiotensin-converting-enzyme inhibitors (n 3), whereas in the phytosterol-enriched group two subjects used β-blockers, two subjects used an angiotensin II antagonist and one subject used a combination of a β-blocker and an angiotensin II-antagonist. All concomitant medication was maintained unchanged during the study. The participants were requested to retain their normal lifestyle and continue their standard lipid-lowering diet throughout the trial. The protocol was approved by the ethical committees of the four institutions and written informed consent was obtained from all subjects.

Study design

The study was a double-blind, randomized, placebo-controlled clinical trial over 4 weeks. The study consisted of three sequential phases: screening (week − 4); diet counselling (week − 4 to week − 1); active treatment (week 0 to week 4). After screening, all eligible subjects were enrolled into the study. At the start of the study (week − 4) participants were encouraged to continue their standard lipid-lowering diet throughout the trial (American Heart Association step I diet (NCEP, 2001): < 30 % total energy/d from fat (maximum 10 % saturated fat) and cholesterol < 300 mg/d). The subject received oral and written instructions on the diet by dietitians. Dietary counselling, through expert questioning, took place twice, at week − 4 and − 1. At study visits, subjects were asked for possible changes in diet habits.

Baseline plasma lipid and lipoprotein values were measured four times during screening and diet counselling (weeks − 4, − 2, − 1 and 0). Thereafter, subjects were randomly assigned to receive either three chocolate servings/d, containing a tall oil–phytosterol mixture (total dosage 1·8 g/d) or three placebo-matched chocolate servings to be consumed with meals for 4 weeks. Blood samples for efficacy and safety measures were obtained at weeks 3 and 4. During the study participants were asked to report any important deviation in lifestyle as well as intercurrent illnesses and use of concomitant medication. Routine blood chemistry (aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) bilirubin, alkaline phosphatase, glucose, uric acid, urea, creatinine, thyroid stimulating hormone (TSH)), haematology (haemoglobin, packed cell volume, erythrocyte and leucocyte count, platelet count) and urinalysis were performed. All reported or observed clinical adverse effects and clinically significant laboratory adverse effects were recorded. Compliance was monitored by counting the chocolates returned and measured by the ratio of the number of chocolates consumed to the number that should have been consumed between weeks 0 and 4, i.e. eighty-four chocolates.
The phytosterols, derived from tall-oil soap, are a proprietary mixture of four phytosterols (β-sitostanol, sitostanol, campesterol, campestanol) in the approximate ratio of 60:20:14:3. The mixture contains 18% (w/w) sitostanol. Some minor phytosterols such as stigmastanol may be present in amounts less than 1% each of the total mixture. The two chocolate preparations (placebo and phytosterol-enriched chocolates) were foil-seal packaged and were indistinguishable in colour, taste, absorbable fat content and energy value. Each chocolate weighed 10.5 g and contained 260 kJ (62 kcal) energy. The composition of the chocolate is presented in Table 1. Furthermore, each preparation contained 4.5 mg Na and traces of vitamin A (0.018 μg), vitamin C (0.13 mg), Ca (16 mg), Fe (0.15 mg) and dietary fibre (0.12 g). The non-esterified phytosterol–sterol mixture and chocolates were prepared by Forbes Medi-Tech Inc, Vancouver, BC, Canada.

Test and control chocolates

The phytosterols, derived from tall-oil soap, are a proprietary mixture of four phytosterols (β-sitostanol, sitostanol, campesterol, campestanol) in the approximate ratio of 60:20:14:3. The mixture contains 18% (w/w) sitostanol. Some minor phytosterols such as stigmastanol may be present in amounts less than 1% each of the total mixture. The two chocolate preparations (placebo and phytosterol-enriched chocolates) were foil-seal packaged and were indistinguishable in colour, taste, absorbable fat content and energy value. Each chocolate weighed 10.5 g and contained 260 kJ (62 kcal) energy. The composition of the chocolates is presented in Table 1. Furthermore, each chocolate contained 4.5 mg Na and traces of vitamin A (3.9 μg), vitamin C (0.13 mg), Ca (16 mg), Fe (0.15 mg) and dietary fibre (0.12 g). The non-esterified phytosterol–sterol mixture and chocolates were prepared by Forbes Medi-Tech Inc, Vancouver, BC, Canada.

Table 1. Composition of daily dosage of chocolate (31.5 g/d)

<table>
<thead>
<tr>
<th></th>
<th>Placebo chocolate</th>
<th>Phytosterol-enriched chocolate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fat (g/d)</td>
<td>15.0</td>
<td>15.0</td>
</tr>
<tr>
<td>Major fatty acids (g/d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saturated</td>
<td>5.9</td>
<td>6.0</td>
</tr>
<tr>
<td>Monounsaturated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oleic (C18:1cis)</td>
<td>8.0</td>
<td>8.1</td>
</tr>
<tr>
<td>Linoleic (C18:2cis)</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>Polyunsaturated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactose (g/d)</td>
<td>1.8</td>
<td>1.8</td>
</tr>
<tr>
<td>Starch</td>
<td>1.09</td>
<td>0.97</td>
</tr>
<tr>
<td>Stigmasterol</td>
<td>0.26</td>
<td>0.26</td>
</tr>
<tr>
<td>Sitostanol</td>
<td>0.37</td>
<td>0.37</td>
</tr>
<tr>
<td>Campesterol</td>
<td>0.26</td>
<td>0.26</td>
</tr>
<tr>
<td>Campestanol</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>Carbohydrate (g/d)</td>
<td>11.8</td>
<td>11.8</td>
</tr>
<tr>
<td>Sugar</td>
<td>9.7</td>
<td>9.7</td>
</tr>
<tr>
<td>Protein (g/d)</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Cholesterol (mg/d)</td>
<td>4.9</td>
<td>4.9</td>
</tr>
</tbody>
</table>

Lipid and lipoprotein analysis: routine blood chemistry and haematology

Venous blood samples were collected by venipuncture from an antecubital vein after an overnight fast. Plasma and serum were prepared by centrifuging blood for 10 min at 3000 g. Samples were stored at −80 °C. A central laboratory (AML, Antwerpen, Belgium) analysed all blood samples for lipid and lipoprotein levels and routine blood chemistry and haematology. Total cholesterol and triacylglycerol levels were measured using the cholesterol C-system high performance enzymic calorimetric tests CHOD-PAP and GPO-PAP, respectively (Boehringer Mannheim, GmbH, Germany). HDL-cholesterol was measured as described for total cholesterol after precipitation of apolipoprotein B-containing lipoproteins with heparin-manganese. LDL-cholesterol was calculated using the Friedewald formula. Routine blood chemistry and haematology were performed to assess possible adverse effects of phytosterol consumption. Plasma ALAT, γ-glutamyl transpeptidase (γGT), ASAT, bilirubin, albumin, glucose, uric acid, urea and creatinine were determined using commercial test kits (Boehringer Mannheim, GmbH, Diagnostica, Germany). Alkaline phosphatase activity was measured in serum. Haemoglobin concentration, leucocyte cell count, erythrocyte cell count, platelet count and calculation of packed cell volume were performed using a Sysmex microcell F-800 bloodcell counter.

Lathosterol and phytosterol measurements

Serum non-cholesterol sterol levels (μmol/l), including lathosterol (a cholesterol precursor sterol reflecting cholesterol synthesis; Kempen et al. 1988) and phytosterols (stigmasterol, sitostanol, campesterol and sitosterol), were measured using GC following established methodology. Briefly, 0.1 ml plasma was saponified with KOH for 1 h at 37°C. Extracted samples were derivatized with N,O-Bis(trimethylsilyl) trifluoroacetamide and 1% trimethylchlorosilane and injected into a Varian 3400 gas chromatograph (Sunnyvale, CA, USA) equipped with a capillary column (CP-SIL 19CB FS 25×0.25 (0.2); Chrompack, Middelburg, The Netherlands) and a data processing system, using flame ionisation as detection and coprostanol as an internal standard. Campesterol, stigmasterol and sitosterol were identified using authenticated standards (Sigma, St Louis, MO) (Koopman et al. 1987; Hodis et al. 1991). Plasma phytosterols were determined twice from the same sample and the mean value of the two determinations was used in the statistical analysis.

Non-cholesterol sterols in serum are transported in a mixture with cholesterol in lipoproteins, up to 90%, by LDL. Accordingly, concentrations of non-cholesterol sterols usually have positive correlation coefficients with that of cholesterol. To eliminate the effect of changing lipid and lipoprotein levels, the non-cholesterol sterol values are standardized and expressed in terms of 100× mmol/mol cholesterol, that is, in ratios to serum total cholesterol. Non-cholesterol sterols were measured pre-weeks 1 and 0 and post-treatment (weeks 3 and 4). The sterol measurements were performed in the lipid research laboratory of the University Medical Centre Nijmegen, The Netherlands.

Statistical methods

Analyses were conducted on the per-protocol population, defined as subjects with an average LDL-cholesterol at weeks −2 and −1 of ≥3.5 mmol/l; less than 15% variation in LDL-cholesterol between weeks −2 and −1; triacylglycerols <4.0 mmol/l at each of weeks −2, −1 and 0; 80% compliance; no more than 3 d off treatment before the week 4 visit; week 4 visit no more than 6 weeks after start of treatment. These information included demographics, vital signs, findings on physical examination, and laboratory measurements (lipids, haematology, chemistry). The weight, BMI, blood pressure and lipid and lipoprotein values obtained at
weeks −2, −1 and 0 were averaged to obtain a single baseline value. Differences between intervention groups at baseline were evaluated by the χ² test for categorical variables and by the t test for continuous variables.

The primary efficacy measurements were the changes in plasma total cholesterol and LDL-cholesterol. The outcome variables, including absolute total and LDL-cholesterol levels at weeks 3 and 4 and the absolute and percentage (relative) changes in total and LDL-cholesterol levels from baseline to each post-treatment visit were analysed using analysis of covariance, with treatment group included as the only main effect. The baseline value was included as a covariate in analysis of the post-treatment values and the absolute changes from baseline. The mean post-treatment values (and 95 % CI) presented are least squares means, adjusted for any difference in the baseline value between the two treatment groups.

Similar analyses were performed for the secondary efficacy measurements (triacylglycerol, HDL-cholesterol and LDL:HDL) and non-cholesterol sterol measurements, with the difference that the average of the values obtained at weeks 3 and 4 was used as the post-treatment value.

The measurements made at week 4 were used as the post-treatment values for routine blood chemistry, weight, BMI and blood pressure. If a measurement was not available at week 4, the value obtained at week 3 was carried forward. The post-treatment value and change from baseline were compared between treatment groups using analysis of covariance, including the baseline value as a covariate. The significance of the difference from 0 of the change from baseline within each group was determined either by the paired t test or by Wilcoxon’s matched pairs signed ranks test, as appropriate.

The proportion of subjects reporting any treatment-emergent adverse event was compared between treatment groups using the χ² test. Compliance was compared between treatment groups using the Mann–Whitney U test. Statistical analyses were performed using SAS Version 8 (SAS Institute Inc, Cary, NC, USA).

**Results**

**Subjects**

Seventy subjects were enrolled in the two study groups.

One subject randomized to the placebo group discontinued because of an adverse event, and one subject given phytosterol-enriched chocolates withdrew consent after starting consumption of the study product. There was no difference between treatment groups with respect to the proportion of subjects who completed the trial (97 %).

Results presented are based on the per-protocol analysis. In total, eight subjects were excluded from the per-protocol analysis, four in the placebo group and four in the phytosterol-enriched-chocolate group due to more than 15 % variation in LDL between week −2 and −1 (n 1 per group), triacylglycerol levels ≥4·0 mmol/l at any of weeks −2, −1 or 0 (n 1 per group) and compliance less than 80 % (n 2 per group). At baseline, the placebo group (n 31) and phytosterol-enriched-chocolate group (n 31) were similar in sex distribution, mean age, BMI and blood pressure (Table 2). All participants had primary hypercholesterolaemia, as reflected by high LDL-cholesterol levels, with no significant difference between the two treatment groups in lipid or lipoprotein variables (Tables 3 and 4). Baseline haematology and chemistry results indicated no significant difference between treatment groups (results not shown).

The chocolates were tolerated well by all subjects and no significant clinical or laboratory safety side effects were observed. There were no reported abnormalities of stool consistency or colour. Compliance was 99·4 % in the placebo group and 96·7 % in the phytosterol-enriched-chocolate group, with no statistically significant difference between treatment groups.

No significant change in BMI was found after treatment (25·3 (95 % CI 24·2, 26·3) kg/m² in the placebo group; 25·2 (95 % CI 24·1, 26·3) kg/m² in the phytosterol-enriched-chocolate group). Subjects given phytosterol-enriched chocolates experienced significant decreases in both systolic (−6·6 mmHg, P<0·005) and diastolic (−2·4 mmHg, P<0·01) blood pressure during treatment. However, there was no significant difference between treatment groups post-treatment.

**Effect of treatment on plasma lipid and lipoprotein levels**

The mean absolute total plasma cholesterol and LDL-cholesterol levels during the treatment period are presented in Table 3. In the placebo group, total and LDL-cholesterol levels did not change during the study. The phytosterol-
**Table 3. Effect of phytosterol-enriched chocolates compared with placebo chocolates on total cholesterol and low-density lipoprotein-cholesterol concentrations in subjects with primary hypercholesterolaemia.**

<table>
<thead>
<tr>
<th></th>
<th>Total cholesterol (mmol/l)</th>
<th>LDL-cholesterol (mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline (mean ± SD)</td>
<td>Post-treatment (mean ± SD)</td>
</tr>
<tr>
<td>Placebo</td>
<td>6.44 ± 0.91</td>
<td>6.26 ± 0.94</td>
</tr>
<tr>
<td>Phytosterol</td>
<td>6.79 ± 0.91</td>
<td>6.68 ± 0.92</td>
</tr>
</tbody>
</table>

**Note:** For both the campesterol and sitosterol values, there was no difference between the two groups at baseline. In the placebo group, no significant change in campesterol levels during treatment was found. However, subjects given phytosterol-enriched chocolates experienced significant absolute and relative increases in campesterol levels post-treatment. There were highly significant differences between treatment groups with respect to campesterol levels post-treatment, and in the absolute and relative changes in campesterol levels from baseline (all P<0.001). For the sitosterol levels both groups experienced statistically significant absolute and relative increases during treatment, but the changes among the subjects given phytosterol-enriched chocolates were substantially greater than those in the placebo group. There were highly significant differences between treatment groups.
with respect to sitosterol levels post-treatment, and in the absolute and relative changes in sitosterol levels from baseline (all \(P<0.001\)). Stigmasterol and sitostanol were not detectable in plasma.

### Discussion

This randomized, double-blind, placebo-controlled trial demonstrates that a tall oil-derived phytosterol mixture, containing 18 % (w/w) sitostanol, incorporated into a dietary chocolate consumed three times a day with meals, effectively reduces plasma total and LDL-cholesterol concentrations in mildly hypercholesterolaemic subjects. In the phytosterol-enriched-chocolate group the mean LDL-cholesterol level was reduced by 0.49 mmol/l (10.3 %). The reduction in LDL-cholesterol produced by the phytosterol ester mixture was already evident after 3 weeks of consumption and even further decreased after 4 weeks.

In agreement with other studies phytosterols did not affect HDL-cholesterol and triacylglycerol concentrations (Jones et al. 1999; Moghadasian & Frolich, 1999). Due to the unchanged HDL-cholesterol concentration, the phytosterol-enriched chocolates changed LDL-cholesterol/HDL cholesterol in a favourable way.

The phytosterol-enriched chocolates were palatable and well-tolerated, which is consistent with safety data from previous studies.

Phytosterol lower serum cholesterol concentrations extrinsically by reducing the absorption of cholesterol from the gut by competing for the limited space for cholesterol in mixed micelles, which deliver mixtures of lipids for absorption into the mucosal cells (Lees et al. 1977; Mattson et al. 1982; Heinemann et al. 1993; Gylling et al. 1997). The efficacy of the various phytosterols in lowering circulating lipid concentration was shown previously for both unsaturated (sterol) (Lees et al. 1977; Westrate et al. 1998) and saturated (stanol) phytosterols (Miettinen et al. 1995; Gylling et al. 1995; Jones et al. 1998) either esterified or non-esterified to fatty acids (for reviews, see Moghadasian & Frolich, 1999; Law, 2000).

The most predominant phytosterols and phytostanols are sitosterol, campesterol, stigmasterol and sitostanol and campestanol, respectively. Previous studies have suggested that phytosterols differ from phytostanols as the latter are virtually unabsorbable (<1 %) in the intestine, whereas 4–5 % of phytosterols are absorbed (Heinemann et al. 1993; Gylling & Meittinen, 1994). It has been suggested that the intestinal absorbability of phytosterols and stanols is inversely related to its inhibiting effects on cholesterol absorption. So, it was generally believed that phytostanols are more effective in reducing plasma cholesterol than phytosterols. However, recent literature shows that both serum plantstanol and sterol concentration increase with consumption of phytosterols (Hallikainen et al. 2000). In line with this observation, randomised comparisons in four trials show no difference in the cholesterol-lowering capacity of either sterols or stanols (Westrate et al. 1998; Hallikainen et al. 2000; Jones et al. 2000; Normen et al. 2000), indicating that a mixture of phytosterols and stanols may be as effective as stanols alone.

In the present study a phytosterol mixture derived from tall oil was used in which the two main components were \(\beta\)-sitosterol and sitostanol. We chose to use a sterol–stanol mixture above a single entity for two main reasons. First, sitostanol accounts for about 20 % of the total mixture, potentially the most potent inhibitor of cholesterol uptake from the intestine. Despite having only about 0.25 of the amount of sitostanol as a sitostanyl ester preparation, our phytosterol ester mixture has a cholesterol-lowering effect at a dosage of 1.8 g/d. So, the amount of sitostanol in our mixture is sufficient for a significant cholesterol-lowering effect. Second, there is a very significant cost advantage to using a mixture over the single entity; this is particularly important if phytosterols are to be used as food additives.

It has been suggested that the use of phytosteryl esters for cholesterol lowering is safer than the use of phytosterol esters because the latter may cause a marked increase in serum phytosterols in individuals with high sterol absorption efficiency, a condition resembling atherogenic

---

### Table 4. Effect of phytosterol-enriched chocolates compared with placebo chocolates on high-density lipoprotein-cholesterol and triacylglycerol (TAG) concentrations and on low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol in subjects with primary hypercholesterolaemia

(Mean values and 95 % confidence intervals)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Baseline (n 31)†</th>
<th>Post-treatment (n 31)‡</th>
<th>Change (%)§</th>
<th>(P)¶</th>
<th>(P)¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDL (mmol/l)</td>
<td>Mean (95 % CI)</td>
<td>Mean (95 % CI)</td>
<td>Mean (95 % CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1.46 (1.33, 1.58)</td>
<td>1.36 (1.29, 1.42)</td>
<td>2.6 (-8.0, 2.9)</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Phytosterol</td>
<td>1.33 (1.21, 1.45)</td>
<td>1.37 (1.31, 1.44)</td>
<td>0.1 (-5.4, 5.6)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>LDL/HDL</td>
<td>Placebo</td>
<td>3.35 (3.04, 3.65)</td>
<td>3.59 (3.38, 3.80)</td>
<td>5.3 (-0.6, 11.2)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Phytosterol</td>
<td>3.67 (3.36, 3.97)</td>
<td>3.45 (3.03, 3.45)</td>
<td>7.2 (-13.1, -1.4)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>Placebo</td>
<td>1.33 (1.12, 1.55)</td>
<td>1.50 (1.24, 1.75)</td>
<td>0.2 (-9.4, 8.9)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Phytosterol</td>
<td>1.60 (1.38, 1.82)</td>
<td>1.53 (1.28, 1.79)</td>
<td>1.4 (-7.8, 10.5)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

† Baseline values of all parameters are the average of three measurements (weeks 2, 1 and 0).
‡ Post-treatment values represent the mean of two measurements (weeks 3 and 4).
§ Change (%) is the mean of the individual percentage change.
¶ \(P\) value for the within-treatment group (Wilcoxon signed ranks test on absolute changes from baseline (similar values for both week 3 and week 4)).
\(P\) value for the between-treatment groups (analysis of covariance of post-treatment values).
Table 5. Effect of phytosterol-enriched chocolates compared with placebo chocolate on the plasma cholesterol precursor lathosterol and phytosterol concentrations in subjects with primary hypercholesterolaemia*  
(Mean values and 95% confidence intervals)

<table>
<thead>
<tr>
<th></th>
<th>Baseline†</th>
<th>Post-treatment‡</th>
<th>Change (%)§</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>95% CI</td>
<td>Mean</td>
</tr>
<tr>
<td>Lathosterol μmol/l serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>6.06</td>
<td>4.99, 7.14</td>
<td>6.78</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>6.96</td>
<td>5.89, 8.04</td>
<td>7.21</td>
</tr>
<tr>
<td>Campesterol μmol/l serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>13.25</td>
<td>11.52, 14.98</td>
<td>12.77</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>11.35</td>
<td>9.62, 13.08</td>
<td>17.80</td>
</tr>
<tr>
<td>Sitosterol μmol/l serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>8.96</td>
<td>7.82, 10.10</td>
<td>9.25</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>7.97</td>
<td>6.83, 9.11</td>
<td>14.62</td>
</tr>
<tr>
<td>Lathosterol 10^2 mmol/mol cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>91.4</td>
<td>77.2, 105.6</td>
<td>101.0</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>102.8</td>
<td>88.6, 117.0</td>
<td>115.5</td>
</tr>
<tr>
<td>Campesterol 10^2 mmol/mol cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>200.8</td>
<td>175.5, 226.1</td>
<td>192.1</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>169.4</td>
<td>144.1, 194.7</td>
<td>283.6</td>
</tr>
<tr>
<td>Sitosterol 10^2 mmol/mol cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo chocolates</td>
<td>135.9</td>
<td>119.4, 152.4</td>
<td>139.5</td>
</tr>
<tr>
<td>Phytosterol-enriched chocolates</td>
<td>118.8</td>
<td>102.3, 135.3</td>
<td>231.9</td>
</tr>
</tbody>
</table>

* For details of subjects, chocolates and procedures, see Tables 1 and 2 and p. 480.  
† Baseline values of all parameters are the average of two measurements (week 1 and 0).  
‡ Post-treatment values represent the mean of two measurements at week 3 and week 4.  
§ Change (%) is the mean of the individual percentage change.  
‖ P value for the within-treatment group (Wilcoxon signed ranks test on absolute changes from baseline).  
‖‖ P value for the between-treatment groups (analysis of covariance of post-treatment values).
Phytosterolaemia or sitosterolaemia (Lutjohann & von Bergmann, 1997). In the present study, we showed that 1·8 g tall oil-derived phytosterols/d significantly increased plasma sitosterol and campesterol concentrations by 95·8 % and 64·1 %, respectively. This high relative increase in phytosterol concentration has also been reported by Westrate et al. (1998) who showed that consumption of 3·24 g phytosterols/d increased serum sitosterol and campesterol levels by an average of 40 % and 70 %, respectively. In addition, recently, Jones et al. (2000) showed an increase of 32·5 % and 71·6 % in sitosterol and campesterol levels, respectively, after 3 weeks of phytosterol ester diet (1·84 g/d).

Because extremely high blood levels of phytosterols have been associated with atherosclerosis in subjects homozygous for familial phytosterolaemia the lowest serum levels of sterols might be desirable. In the general population, given a dietary intake of 160–360 mg phytosterols/d, reported serum levels of sitosterol are 3·0–17 mg/l (Miettinen et al. 1990; Gluck et al. 1991; Stalenhoef et al. 2001). This wide range in a normal population suggests considerable individual variability in the handling of various phytosterols. In a recent review of the genetic basis of sitosterolaemia (Lee et al. 2001) it is reported that phytosterol concentrations in control subjects are in general less than 10 mg/l, whereas homozygous patients with sitosterolaemia have values greater than 80 mg/l up to 600 mg/l. Heterozygous carriers for sitosterolaemia have values higher than 10 mg/l but none higher than 20 mg/l and are otherwise biochemically and clinically healthy.

In our study the sitosterol concentration increased from an average of 3·5 mg/l to a maximum of 6·1 mg/l, still within the normal range reported among healthy control subjects. Indeed, the sitosterol concentration in serum or in lipoprotein cholesterol mixtures that is needed for enhanced development of atheromatosis is not known and further studies on the effect of variability in phytosterol concentration within the normal range on atherosclerosis are needed.

The inhibition of intestinal cholesterol absorption by phytosterols stimulates de novo hepatic cholesterol synthesis. The cholesterol synthesis rate can be reflected by measuring serum cholesterol precursor lathosterol (Kempen et al. 1988). We have shown that lathosterol concentration is increased by phytosterol treatment in accordance with the literature (Gylling & Miettinen, 1994, 1997; Jones et al. 2000). So, the inhibition of intestinal cholesterol absorption by phytosterols is accompanied by a compensatory increase in cholesterol synthesis. However, the reduced absorption lowers serum cholesterol despite the compensatory increase in cholesterol synthesis.

Subjects with mild hypercholesterolaemia are recommended to eat foods low in saturated fat and cholesterol, as described in the American Heart Association step I diet. A limitation in the use of chocolate as a vehicle for phytosterols is that the intake of extra energy (779 kJ (186 kcal)/d) with 72 % energy from fat, 40 % as saturated fat. So, assuming an energy requirement of 50-year-old subjects of 10468 kJ (2500 kcal)/d, the daily chocolate intake provides approximately 19 % of the total fat recommendation and 24 % of the saturated fat recommendation. In the present study the adherence to the diet was not recorded by food records and/or nutrition analysis. Most likely, the chocolates increased the total and saturated fat intake, which is not desirable in mildly hypercholesterolaemic subjects on a low-fat, low-cholesterol diet. The potentially increased intake of energy and total and saturated fat did not result in a change in body weight and/or an increase in total and LDL-cholesterol levels in the placebo group in this short-term study. However, we recommend that long-term use of phytosterol-enriched chocolates should be accompanied by dietary advice to replace energy and normal daily fat intake by the same amount provided by the chocolates.

The cholesterol and fat intake may affect the cholesterol-lowering effect of phytosterols (Mattson et al. 1982; Denke, 1995). However, in three recent randomised trials of stanol margarine in which participants were on low-fat, low-cholesterol diets, the reductions in serum concentrations of LDL-cholesterol were similar to those found in other trials in which the intake of dietary fat was higher (Hallikainen & Uusitupa, 1999; Jones et al. 1999; Hallikainen et al. 2000). Furthermore, plant stanols were equally effective in patients taking statins who had mean LDL-cholesterol concentrations of only 2·9 mmol/l (Gylling et al. 1997). Therefore, the total amount of cholesterol and fat in the diet, and its fatty acid composition, is not a major determinant of the plasma cholesterol-lowering effects of plant sterols and stanols. This is presumably due to the fact that not only dietary cholesterol but also biliary cholesterol absorption is inhibited. In the present study, the participants showed a significant decrease in total and LDL-cholesterol in response to phytosterol intake in dietary chocolate compared with dietary chocolate alone, in conjunction with a low-fat, low-cholesterol diet. However, the study was not designed to evaluate the effect of intake on the cholesterol-lowering potential of phytosterols.

Phytosterols have been incorporated into various kinds of foods, now known as functional foods, designed to enhance health or contribute to the reduction of a specific disease risk (Diplock et al. 1999; de Graaf & Stalenhoef, 2000). Because fats are needed to solubilise phytosterol esters, margarines are an ideal vehicle for them, although cream cheese, salad dressing and yoghurt are also used. Mixtures of non-esterified sterols and stanols have the advantage that they can be dispersed in lower-fat-containing foods. Recently, functional foods containing phytosterol mixtures have been recommended in the National cholesterol education program guidelines (Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, 2001) as the next step after dietary advice to bridge the gap before drug therapy is initiated. The development of various kinds of foods containing phytosterols acknowledges the individual variability in taste and food preference and will contribute to increased availability of various phytosterol-enriched foods eaten by most of the population. We have now shown that tall oil phytosterol consumption suspended in a dietary chocolate favourably alters lipid and lipoprotein levels in mildly hypercholesterolaemic subjects.

The reduction of LDL-cholesterol by approximately 10 % during consumption of a mixture of phytosterols in...
chocolates would be expected to decrease coronary events by 20–40% (Law et al., 1994), depending on the length of the consumption period. However, the potential added costs for this functional food could limit consumption in the general population. As stanols and sterols become less expensive, their introduction into the food chain will make them an important innovation in the primary prevention of heart disease. Post-marketing surveillance of this functional food remains obligatory to control long-term safety and efficacy.

We conclude that dietary chocolates enriched with tall oil-derived phytosterols (1.8 g/d) are a suitable strategy to reduce serum cholesterol and LDL concentrations in mildly hypercholesterolemic subjects.

Acknowledgements

The authors wish to thank Magda Hectors of the Lipid Research Laboratory, University Hospital Nijmegen, The Netherlands for expert technical assistance.

References


Cater NB (1999) Historical and scientific basis for the development of plant stanol ester foods as cholesterol lowering agents. European Heart Journal 1, S36–S44.


